David Dadiomov

Title(s)Assistant Professor of Clinical Pharmacy
SchoolUSC School of Pharmacy
Address1969 Zonal Avenue
Health Sciences Campus
Los Angeles CA 90089-9121
Phone+1 323 442 1414
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy. Arch Public Health. 2024 Apr 25; 82(1):58. Varisco TJ, Fish H, Bolin J, Dadiomov D, Hill LG, Essien EJ, Wanat MA, Ginsburg D, Waggener J, Yazdanfard S, Song J, Chi W, Thornton D. PMID: 38664777; PMCID: PMC11044383.
      View in: PubMed   Mentions:
    2. Adverse childhood experiences among California student pharmacists. Ment Health Clin. 2024 Feb; 14(1):1-9. Smith SR, Banuelos L, Trujillo N, Farihi D, Lee S, Truong S, Ly T, Dadiomov D, Kawahara N, Gavaza P. PMID: 38312442; PMCID: PMC10836563.
      View in: PubMed   Mentions:
    3. Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects. Ther Adv Drug Saf. 2023; 14:20420986231213173. Roth W, Dadiomov D, Chu M. PMID: 38074415; PMCID: PMC10702410.
      View in: PubMed   Mentions:
    4. Lowering barriers to naloxone access through a student-led harm reduction program. J Am Pharm Assoc (2003). 2022 Nov 04. Brown M, Tran C, Dadiomov D. PMID: 36443177.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Providing Low-barrier Addiction Treatment Via a Telemedicine Consultation Service During the COVID-19 Pandemic in Los Angeles, County: An Assessment 1 Year Later. J Addict Med. 2023 Jan-Feb 01; 17(1):e64-e66. Kennedy AJ, George JS, Rossetti G, Brown CO, Ragins K, Dadiomov D, Trotzky-Sirr R, Sanchez G, Llamas H, Hurley B. PMID: 35839323; PMCID: PMC9897115.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    6. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic. Harm Reduct J. 2022 06 29; 19(1):69. Dadiomov D, Bolshakova M, Mikhaeilyan M, Trotzky-Sirr R. PMID: 35768817; PMCID: PMC9241266.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    7. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic. Drug Alcohol Depend. 2022 03 01; 232:109291. Dadiomov D, Trotzky-Sirr R, Shooshtari A, Qato DM. PMID: 35033953; PMCID: PMC8750914.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    8. Prevalence and distribution of high-risk prescription opioid use in the United States, 2011-2016. Pharmacoepidemiol Drug Saf. 2021 11; 30(11):1532-1540. McCormick CD, Dadiomov D, Trotzky-Sirr R, Qato DM. PMID: 34435406.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Am J Health Syst Pharm. 2021 03 18; 78(7):613-618. Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. PMID: 33411894; PMCID: PMC7929456.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsPHPublic Health
    10. Safety of Repeated Administration of Parenteral Ketamine for Depression. Pharmaceuticals (Basel). 2020 Jul 13; 13(7). Feifel D, Dadiomov D, C Lee K. PMID: 32668686; PMCID: PMC7408561.
      View in: PubMed   Mentions: 8  
    11. Dissociating the Clinical Role and Economic Value of Intranasal Esketamine. J Manag Care Spec Pharm. 2020 Jan; 26(1):20-22. Dadiomov D. PMID: 31880233; PMCID: PMC10391094.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. The effects of ketamine on suicidality across various formulations and study settings. Ment Health Clin. 2019 Jan; 9(1):48-60. Dadiomov D, Lee K. PMID: 30627504; PMCID: PMC6322816.
      View in: PubMed   Mentions: 13  
    13. Using the LACE Score as a Predictor of Clinical Outcomes in Patients Referred for Inpatient Palliative Care Consultation: A Single-Center Experience. Am J Hosp Palliat Care. 2018 Jul 31; 1049909118793177. Dadiomov D, Keefer P, Smith MA. PMID: 30064238.
      View in: PubMed   Mentions:    Fields:    
    David's Networks
    Concepts (42)
    Derived automatically from this person's publications.
    Co-Authors (4)
    People in Profiles who have published with this person.
    Similar People (59)
    People who share similar concepts with this person.
    Same Department
    Search Department